PharmaEngine, Inc.
Research PharmaEngine, Inc. (4162.TWO) on Bullrun: market cap TWD 8.25B, P/E 15.3, dividend yield 3.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4162.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 8.25B
- P/E15.3
- Dividend yield3.8%
- Financial periodQ2 2026
- RevenueTWD 258.02M
- Net incomeTWD 134.04M
- Free cash flowTWD 98.57M
- Gross margin92.7%
Valuation Snapshot
latest market cap is TWD 8.25B; P/E is 15.3; dividend yield is 3.8%.
Peer valuation comparison
Latest P/E is 15.31x versus a Healthcare sector median of 21.8x (29.8% below).
Latest dividend yield is 3.81% versus a Healthcare sector median of 2.4% (58.8% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 8.25B | 15.3 | 3.5% | 2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2 TWD, yield 3.8%.
About PharmaEngine, Inc.
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
ETFs that hold PharmaEngine, Inc.
US-listed ETFs
PharmaEngine, Inc. is held by 15 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PharmaEngine, Inc.'s market cap?
PharmaEngine, Inc.'s market capitalization is TWD 8.25B.
What is PharmaEngine, Inc.'s P/E ratio?
PharmaEngine, Inc.'s price-to-earnings (P/E) ratio is 15.3.
Does PharmaEngine, Inc. pay a dividend?
PharmaEngine, Inc. has a dividend yield of 3.8%.
What does PharmaEngine, Inc. do?
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.